Loading...
The Value of Pre-Screening in the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Trial
The Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test...
Na minha lista:
| Udgivet i: | J Prev Alzheimers Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5987758/ https://ncbi.nlm.nih.gov/pubmed/29405233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14283/jpad.2017.44 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|